Pancreas Cancer Specialized Program of Research Excelle*

Excelle 胰腺癌专门研究计划*

• 批准号: 7108549
• 负责人: Anton Wellstein
• 金额: $ 21.6万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7108549
• 关键词: health science research; pancreas neoplasms

DESCRIPTION (provided by applicant): The goal of this Specialized Program of Research Excellence (SPORE) in pancreas cancer is to translate outstanding hypothesis-driven basic research into clinical treatment that saves lives. Pancreatic cancer is a devastating cancer that kills patients not just because it may be extremely aggressive but also because it is diagnosed late. This SPORE is a unique collaboration between Georgetown University, Geisinger Health System and INDIVUMED a German Research Institute with a German hospital consortium that brings together an outstanding academic institution, a large regional healthcare system and a German basic and clinical research system to address the biology of pancreatic cancer and clinical care. Project 1 focuses on inhibition of pleiotrophin, a novel heparin-binding growth factor that promotes invasion and metastasis in pancreatic cancer. Project 2 focuses on the role of neuregulins and pleiotrophin in an established model of neuron tumor cell interaction with the goal of developing methods to block neural invasion by malignant pancreas cells that may ultimately aid in disease palliation. Project 3 focuses on recent findings that inhibition of the nuclear receptor coactivator AIB1 within pancreas cancer cells and adjacent endothelium may block signaling from multiple growth factors to enhance apoptosis. The activation of the ras/MAP kinase pathway that occurs in up to 90 percent of pancreas cancer is the focus for novel approaches to radiation sensitization in Project 4. Investigators at Georgetown have developed a rafl antisense inhibitor that is already in Phase I trial and have developed other molecular targets in the pathway that are complementary. In addition, this SPORE is developing the infrastructure and resources to acquire tissues and bodily fluids from patients (Pancreatic Tumor Bank and Serum Detection & Molecular Identification Cores) with an expected 120 curative resections a year. The SPORE will utilize a biostatistical core to insure that all projects have appropriate designs, methods of analysis, and an integrated database for reporting patient outcomes. Further, the SPORE will support developmental projects designed to generate new knowledge and approaches to early detection and promote the development of career tracks dedicated to translational research in pancreatic cancer. This SPORE is also establishing interactions with SPOREs in other institutions as well as with other NCI- and NIH-funded programs to promote the aggressive development of novel therapies for the control of pancreas cancer.

描述（由申请人提供）： 这项胰腺癌专业卓越研究计划 (SPORE) 的目标是将杰出的假设驱动的基础研究转化为挽救生命的临床治疗。胰腺癌是一种毁灭性的癌症，它会导致患者死亡，不仅因为它可能极具侵袭性，还因为它诊断较晚。该 SPORE 是乔治城大学、Geisinger Health System 和 INDIVUMED 之间的独特合作，INDIVUMED 是一家德国研究所与德国医院联盟，汇集了杰出的学术机构、大型区域医疗保健系统以及德国基础和临床研究系统，以解决以下问题的生物学问题：胰腺癌和临床护理。项目 1 重点关注多效蛋白的抑制，多效蛋白是一种新型肝素结合生长因子，可促进胰腺癌的侵袭和转移。项目 2 重点研究神经调节蛋白和多效蛋白在已建立的神经元肿瘤细胞相互作用模型中的作用，目标是开发阻止恶性胰腺细胞侵袭神经的方法，最终有助于缓解疾病。项目 3 重点关注最近的发现，即抑制胰腺癌细胞和邻近内皮细胞内的核受体共激活剂 AIB1 可能会阻断多种生长因子的信号传导，从而增强细胞凋亡。高达 90% 的胰腺癌中发生的 ras/MAP 激酶途径的激活是项目 4 中放射增敏新方法的重点。乔治城大学的研究人员开发了一种 rafl 反义抑制剂，该抑制剂已进入 I 期试验，并已获得批准。在该途径中开发了其他互补的分子靶标。 此外，该 SPORE 正在开发基础设施和资源，以从患者身上获取组织和体液（胰腺肿瘤库和血清检测和分子识别核心），预计每年进行 120 例治愈性切除手术。 SPORE 将利用生物统计核心来确保所有项目都有适当的设计、分析方法和用于报告患者结果的综合数据库。此外，SPORE 将支持旨在产生新知识和早期检测方法的开发项目，并促进致力于胰腺癌转化研究的职业轨迹的发展。该 SPORE 还与其他机构的 SPORE 以及其他 NCI 和 NIH 资助的项目建立互动，以促进控制胰腺癌的新疗法的积极开发。